We sought to determine whether radial left ventricular (LV) asynchrony in patients with heart failure predicts systolic function improvement with cardiac resynchronization therapy (CRT).
Background
We quantified LV wall motion by echocardiography to correlate the effects of CRT on LV systolic function with wall motion synchrony.
Methods
Thirty-four patients underwent echocardiographic phase analysis of LV septal and lateral wall motion and hemodynamic testing before CRT. Phase relationships were measured by the difference between the lateral (ΦL) and septal (ΦS) wall motion phase angles: ΦLS = ΦL − ΦS. The absolute value of ΦLS was used as an order-independent measure of synchrony: |ΦLS| = |ΦL − ΦS|.
Results
Three phase relationships were identified (mean ± SD): type 1 (n = 4; peak positive LV pressure [dP/dtmax] 692 ± 310 mm Hg/s; ΦLS = 5 ± 6°, synchronous wall motion); type 2 (n = 17; dP/dtmax 532 ± 148 mm Hg/s; ΦLS = 77 ± 33°, delayed lateral wall motion); and type 3 (n = 13; dP/dtmax 558 ± 154 mm Hg/s; ΦLS = −115 ± 33°, delayed septal wall motion, triphasic). A large |ΦLS| predicted a larger increase in dP/dtmax with CRT (r = 0.74, p < 0.001). Sixteen patients were studied during right ventricular (RV), LV and biventricular (BV) pacing. Cardiac resynchronization therapy acutely reduced |ΦLS| from 104 ± 41° (OFF) to 86 ± 45° (RV; p = 0.14 vs. OFF), 71 ± 50° (LV; p = 0.001 vs. OFF) and 66 ± 42° (BV; p = 0.001 vs. OFF). A reduction in |ΦLS| predicted an improvement in dP/dtmax in type 2 patients for LV (r = 0.87, p = 0.005) and BV CRT (r = 0.73, p = 0.04).
Conclusions
Echocardiographic quantification of LV asynchrony identifies patients likely to have improved systolic function with CRT. Improved synchrony is directly related to improved hemodynamic systolic function in type 2 patients.
Abbreviations
ANOVA
analysis of variance
AV
atrioventricular
BV
biventricular
CAD
coronary artery disease
CRT
cardiac resynchronization therapy
DCM
dilated (nonischemic) cardiomyopathy
LBBB
left bundle branch block
L-S
lateral-septal
LV
left ventricular
dP/dtmax
peak positive left ventricular pressure
NYHA
New York Heart Association
PATH-CHF
Pacing Therapies for Congestive Heart Failure study
This work was supported by a grant from Guidant Corporation, Brussels, Belgium. The investigators and participating centers of the Pacing Therapies for Congestive Heart Failure (PATH-CHF) Study Group, along with collaborators from the Guidant CHF Research Group, are listed in the Appendix of Circulation 1999;99:2993–3001.